Vela Health

Healthcare · Incentives

Big Pharma, doctors, and why treating symptoms is the best business model

Medical incentives favor treatments you take for life over cures. Here’s where the money goes and how to protect yourself as a patient.

Updated 2026-10-09 · ~4 min read · Educational

By Megan Gadiparthy · molecular & cellular biology and data science · founder of Vela

Not medical advice. Many medications save lives. Don’t stop or change a prescription without talking with your clinician first.

At about 11, I was diagnosed with psoriasis and told I’d need about $30,000 a year in medication for life. Nobody asked how I ate, slept, or handled stress. My mom and I changed how I ate, slept, and recovered, and my skin cleared in about three months.

Cures can shrink a drug market

A 2018 Goldman Sachs report for biotech investors asked, “Is curing patients a sustainable business model?” It cited Gilead’s hepatitis C drugs, which cure most patients. Sales peaked at about $12.5 billion in 2015, then fell sharply as cured patients stopped buying and fewer new patients remained. Treatments people take for decades don’t have that problem.

Follow the money

The best customer is a customer for life

The ideal business sells a subscription people can’t easily quit. In medicine, that’s a daily pill or injection for a chronic condition like high blood pressure, acid reflux, depression, or psoriasis, often taken for life.

Many of these drugs work and prevent real harm. But the system has much stronger incentives to sell management than to fix causes. Nobody gets paid when you sleep better or eat real food.

Drug marketing targets you and your doctor

Only the U.S. and New Zealand allow prescription drug ads aimed at consumers. From 1997 to 2016, U.S. medical marketing grew from $17.7 billion to $29.9 billion, and consumer ads from $2.1 billion to $9.6 billion. More than $20 billion of the 2016 total targeted doctors and other health professionals through sales visits, free samples, sponsored talks, and meals. In a study of hundreds of thousands of U.S. doctors, even one sponsored meal, averaging under $20, was linked to more prescriptions of the promoted brand-name drug. Most doctors believe they aren’t influenced.

The system pushes doctors toward prescriptions

Most doctors want to help, but this system excels at emergencies, surgery, and infections and is much weaker at the daily drivers of chronic disease.

The industry outspends all others on lobbying

According to OpenSecrets, the pharmaceutical and health products industry consistently spends more on federal lobbying than any other industry. That money shapes drug pricing rules, patents, and insurance coverage, and is one reason prices stay high and prevention gets little attention.

Lifestyle can rival drugs

In the Diabetes Prevention Program, high-risk adults who changed their diet and exercised about 150 minutes a week cut their risk of type 2 diabetes by 58%. The drug metformin cut it by 31%. The system rarely builds care around lifestyle results like that, because there’s nothing to sell.

Modern medicine still saves lives

Antibiotics, vaccines, insulin, surgery, emergency care, and modern biologics for severe psoriasis have saved and changed millions of lives. Some conditions need medication no matter how well you live. Use medicine for what it does best, and own the daily basics no prescription can replace.

How to be a smarter patient

Bring your own data

Track sleep, food, stress, and symptoms, and you’ll bring weeks of patterns to an 18-minute visit instead of a vague memory. The visit can then focus on causes, not refills. A short daily check-in is the easiest way to start.

Selected sources

  1. Kim T. Goldman Sachs asks in biotech research report: “Is curing patients a sustainable business model?” CNBC. 2018. cnbc.com
  2. Centers for Medicare & Medicaid Services. National Health Expenditure Data: Historical. cms.gov
  3. Centers for Disease Control and Prevention. Fast Facts: Health and Economic Costs of Chronic Conditions. cdc.gov
  4. Ledley FD, et al. Profitability of large pharmaceutical companies compared with other large public companies. JAMA. 2020. DOI: 10.1001/jama.2020.0442
  5. Mulcahy AW, et al. International Prescription Drug Price Comparisons: Estimates Using 2022 Data. RAND Corporation. 2024. rand.org
  6. National Center for Health Statistics. Health, United States: prescription drug use. cdc.gov
  7. Schwartz LM, Woloshin S. Medical marketing in the United States, 1997–2016. JAMA. 2019. DOI: 10.1001/jama.2018.19320
  8. DeJong C, et al. Pharmaceutical industry–sponsored meals and physician prescribing patterns for Medicare beneficiaries. JAMA Intern Med. 2016. DOI: 10.1001/jamainternmed.2016.2765
  9. Neprash HT, et al. Association of primary care visit length with potentially inappropriate prescribing. JAMA Health Forum. 2023. DOI: 10.1001/jamahealthforum.2023.0052
  10. Adams KM, Kohlmeier M, Zeisel SH. Nutrition education in U.S. medical schools: latest update of a national survey. Acad Med. 2010. DOI: 10.1097/ACM.0b013e3181eab71b
  11. OpenSecrets. Industries: Pharmaceuticals/Health Products, lobbying. opensecrets.org
  12. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002. DOI: 10.1056/NEJMoa012512
  13. Centers for Medicare & Medicaid Services. Open Payments data. openpaymentsdata.cms.gov

Want more guides like this?

Get guides in your inbox while we build early access, or keep reading now.

Email me guides More guides